2023
Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety Scale
2022
Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.Peer-Reviewed Original ResearchAdvanced genitourinary cancersGenitourinary cancersExpectation of cureQuality of lifeSide effectsMetastatic genitourinary cancerProportion of patientsStart of therapyMajority of patientsMonths of treatmentRenal cell carcinomaSevere side effectsLongitudinal studyMedian ageClinical outcomesImmunotherapy treatmentCell carcinomaPatients' perceptionsImmunotherapyPatientsGreater efficacyTumor progressionCancerCancer treatmentTime points
2020
645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis
Dizman N, Greenberg M, Newman A, Skupsky J, Hsu J, Zengin Z, Salgia N, Meza L, Chawla N, Salgia S, Malhotra J, Pal S. 645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis. Journal For ImmunoTherapy Of Cancer 2020, 8: a682-a682. DOI: 10.1136/jitc-2020-sitc2020.0645.Peer-Reviewed Original ResearchICI therapySide effectsSystemic inflammationT cellsImmune checkpoint inhibitor therapyFrequent dose-limiting toxicityCandidate therapeuticsCenter Institutional Review BoardFavorable drug profileSigns of colitisCheckpoint inhibitor therapyImmune checkpoint inhibitorsDose-limiting toxicityMinimal systemic absorptionRegulatory T cellsAdoptive transfer modelAnti-inflammatory effectsSite of ulcerationT cell proliferationLife-threatening cancerRodent pharmacokinetic studyCancer-killing abilityInstitutional review boardActive colitisICI colitis